Cargando…

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA(®) observational database: a cohort study

BACKGROUND: HLA-B*57:01 screening was added to clinical care guidelines in 2008 to reduce the risk of hypersensitivity reaction from abacavir. The uptake of HLA-B*57:01 screening and incidence of hypersensitivity reaction were assessed in a prospective clinical cohort in the United States to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mounzer, Karam, Hsu, Ricky, Fusco, Jennifer S., Brunet, Laurence, Henegar, Cassidy E., Vannappagari, Vani, Stainsby, Chris M., Shaefer, Mark S., Ragone, Leigh, Fusco, Gregory P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334426/ https://www.ncbi.nlm.nih.gov/pubmed/30651100 http://dx.doi.org/10.1186/s12981-019-0217-3

Ejemplares similares

Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B*5701 Screening as a Risk‐Mitigation Measure
por: Stainsby, Chris M., et al.
Publicado: (2018)

Two‐drug antiretroviral regimens: an assessment of virologic response and durability among treatment‐experienced persons living with HIV in the OPERA(®) Observational Database
por: Pierone, Gerald, et al.
Publicado: (2019)

Antiretroviral therapy and liver disorders in the OPERA(®) cohort
por: Wohlfeiler, Michael, et al.
Publicado: (2020)

Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes
por: Hsu, Ricky K., et al.
Publicado: (2023)

341. Risk of Type 2 Diabetes Mellitus after Antiretroviral Therapy Initiation in Individuals Living with HIV in the United States
por: Hsu, Ricky, et al.
Publicado: (2019)

978. Changes in BMI Associated with Antiretroviral Regimens in Treatment-Experienced, Virologically Suppressed Individuals Living with HIV
por: Mounzer, Karam, et al.
Publicado: (2019)

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
por: Small, Catherine Butkus, et al.
Publicado: (2017)

936. Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions Following Initiation of Commonly Prescribed Antiretrovirals
por: Lackey, Philip, et al.
Publicado: (2018)

Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Updated Meta-analysis of Data from Clinical Trials
por: Nan, Cassandra, et al.
Publicado: (2017)

Comparison of Methods for In-House Screening of HLA-B*57:01 to Prevent Abacavir Hypersensitivity in HIV-1 Care
por: De Spiegelaere, Ward, et al.
Publicado: (2015)

Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials
por: Nan, Cassandra, et al.
Publicado: (2018)

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice
por: Lackey, Philip, et al.
Publicado: (2016)

1284. Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens
por: Pierone, Gerald, et al.
Publicado: (2022)

1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA(®) Cohort
por: Hsu, Ricky K, et al.
Publicado: (2023)

1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort
por: Sension, Michael, et al.
Publicado: (2023)

886. The Impact of the COVID-19 Pandemic on Clinical Follow-Up, Monitoring and Regimen Discontinuation for People Living with HIV in the US
por: Pierone, Gerald, et al.
Publicado: (2021)

Unravelling the Proteomics of HLA-B*57:01(+) Antigen Presenting Cells during Abacavir Medication
por: Haukamp, Funmilola Josephine, et al.
Publicado: (2022)

2483. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States
por: Pierone, Gerald, et al.
Publicado: (2019)

HLA-B*5701 testing to predict abacavir hypersensitivity
por: Ma, Joseph D., et al.
Publicado: (2010)

Rapid Detection of HLA-B*57:01-Expressing Cells Using a Label-Free Interdigitated Electrode Biosensor Platform for Prevention of Abacavir Hypersensitivity in HIV Treatment
por: Chan, Jianxiong, et al.
Publicado: (2019)

Psychiatric Symptoms in Patients Receiving Dolutegravir
por: Fettiplace, Anna, et al.
Publicado: (2017)

Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors
por: Sooda, Anuradha, et al.
Publicado: (2022)

1265. Effectiveness and Durability of Dolutegravir (DTG)-Based Regimens in Older People Living with HIV (PLWH) from the Veterans Aging Cohort Study (VACS)
por: Yan, Lei, et al.
Publicado: (2022)

The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome
por: Fodor, James, et al.
Publicado: (2019)

Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity
por: Metushi, Imir G., et al.
Publicado: (2015)

Chemical modification of the 6'-amino cyclopropyl of abacavir eliminates HLA-B*57:01-restricted CD8+ T-cell activation without loss of antiviral activity
por: Alhaidari, Mohammad, et al.
Publicado: (2014)

Weight gain before and after switch from TDF to TAF in a U.S. cohort study
por: Mallon, Patrick WG, et al.
Publicado: (2021)

Prevalence of HLA-B*5701 and Its Relationship with Abacavir Hypersensitivity Reaction in Iranian HIV-Infected Patients
por: Baniasadi, Shadi, et al.
Publicado: (2016)

Prevalence of the HLA-B*5701 Allele and Abacavir Hypersensitivity in Saudi HIV Patients: A Multicenter Study
por: Alsaeed, Ali, et al.
Publicado: (2023)

Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides
por: Mallon, Patrick W G, et al.
Publicado: (2021)

Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens
por: Mounzer, Karam, et al.
Publicado: (2022)

1582. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year
por: Sension, Michael G, et al.
Publicado: (2022)

A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno
por: Senatore, C, et al.
Publicado: (2014)

Abs No: HLA-A*31:01 positive hypersensitive patient
por: Lichtenfels, Maike, et al.
Publicado: (2014)

Evaluation of a pharmacogenetic test in Thailand for abacavir hypersensitivity screening in human immunodeficiency virus infection
por: Chonlaphat, Sukasem, et al.
Publicado: (2014)

1592. Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine Among People with HIV with Detectable Viral Loads at Initiation: Trio Cohort Study
por: Elion, Rick A, et al.
Publicado: (2023)

Benchmarking HIV Quality Measures in the US OPERA HIV Cohort
por: Heglar, Robert, et al.
Publicado: (2019)

Low frequency of hypersensitivity reactions to abacavir in HIV infected patients in a referral center in Bahia, Brazil
por: Barreto, Raphael Gusmão, et al.
Publicado: (2019)

Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report
por: Koech, Mathew K., et al.
Publicado: (2022)

Abacavir forms novel cross-linking abacavir protein adducts in patients
por: Meng, Xiaoli, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ku7hhat0p54kj1mjobo1vffiqv